Diabetes Drug Notes 1st Edition by Miles Fisher, Gerard McKay, Andrea Llano ISBN 1119785022 9781119785026

Diabetes Drug Notes 1st Edition by Miles Fisher, Gerard A. McKay, Andrea Llano – Ebook PDF Instant Download/Delivery: 1119785022, 978-1119785026

Full dowload Diabetes Drug Notes 1st Edition after payment

 

 

Product details:

ISBN 10: 1119785022

ISBN 13: 978-1119785026

Author:  Miles Fisher, Gerard A. McKay, Andrea Llano 

Diabetes Drug Notes 1st Edition: 

DIABETES DRUG NOTES
Diabetes is becoming more common in both older and younger generations and in keeping with this escalation in cases, there are an ever increasing number of drugs and drug classes that are suitable to treat hyperglycaemia. In a unique blend of diabetes practice, clinical pharmacology, and cardiovascular medicine, Diabetes Drug Notes describes the principles of clinical pharmacology with regards to diabetes prescribing. Each drug class for the treatment of diabetes is covered in detail, along with the effect on the cardiovascular and renal systems caused by each drug. Building upon the success of their “Drug Notes” series for Practical Diabetes and their “Drugs for Diabetes” series in the British Journal of Cardiology, the team of experts focuses on the glycaemic management of type 1 and type 2 diabetes, with other effects of antidiabetic drugs covered as well.

Diabetes Drug Notes also includes:

• Comprehensive and up-to-date coverage of the drugs for the glycaemic management of patients with type 1 or type 2 diabetes
• Expert reflection on prescribing considerations for special groups, as well as common pitfalls in prescribing
• Detailed case histories to illustrate relevant information
• Summaries of recent guidelines related to diabetic intervention

Diabetes Drug Notes is a user-friendly guide for a general diabetes medical, nursing, and pharmacology readership, as well as those who support them.

 

Diabetes Drug Notes 1st Edition Table of contents:

1. Clinical pharmacology of antidiabetic drugs

• Andrea Llano, Gerry McKay, and Ken Paterson

Introduction

• Clinical Pharmacology
• Drug Metabolism and Elimination
• Drug Development and Clinical Trials
• Drug Licensing of Antidiabetic Drugs
• Development and Licensing of Insulin
• Development and Approval of Biosimilar Insulin
• Pharmacovigilance
• Pharmacoeconomics
• Future Developments in Diabetes Clinical Pharmacology

2. Metformin

• Joseph Timmons and James Boyle
• Introduction
• Pharmacology
• Mechanism of Action
• Glycaemic Efficacy
• Safety and Side Effects
• Metformin in Type 1 Diabetes
• Place of Metformin in Current and Future Practice

3. Sulfonylureas and meglitinides

• Joseph Timmons and James Boyle
• Introduction
• Pharmacology
• Glycaemic Efficacy
• Safety and Side Effects
• Outcome Trials
• Meglitinides
• Place of Sulfonylureas and Meglitinides in Current and Future Practice

4. DPP-4 inhibitors

• Sharon Mackin and Gemma Currie
• Introduction
• Pharmacology
• Glycaemic Efficacy
• Safety and Side Effects
• Outcome Trials
• Renal Outcomes
• The Place of DPP-4 Inhibitors in Current and Future Practice

5. SGLT2 inhibitors

• Miles Fisher, Andrea Llano, and Gerry McKay
• Introduction
• Pharmacology
• Glycaemic Efficacy
• Side Effects and Safety
• Outcome Trials
• Renal Outcome Trials
• Heart Failure Outcome Trials
• SGLT2 Inhibitors in Type 1 Diabetes
• Use of SGLT2 Inhibitors in Other Diseases
• Dare-19
• Place of SGLT2 Inhibitors in Current and Future Practice

6. GLP-1 receptor agonists

• Catherine Russell and John Petrie
• Introduction
• Pharmacology
• Glycaemic Efficacy and Effect on Weight
• Side Effects and Safety
• Outcome Trials
• Use of GLP-1 Receptor Agonists in Other Diseases
• Place of GLP-1 Receptor Agonists in Current and Future Practice

7. Animal and human insulins

• Ken Paterson
• Introduction
• Production and Pharmacokinetic Modifications
• Hypoglycaemia and Human Insulin
• Intensified Insulin Therapy
• Place of Human Insulin in Current and Future Therapy

8. Short-acting insulin analogues

• Kate Hughes and Gerry McKay
• Introduction
• Factors Affecting Absorption and Metabolism of Short-acting Insulin
• Manufacturing Insulin Analogues
• Short-acting Insulin Analogues
• Second-generation Ultrafast-acting Insulin Analogues
• Other Attempts to Improve Insulin Absorption and Inhaled Insulin
• Place of Short-acting Insulin Analogues in Current and Future Practice

9. Long-acting insulin analogues

• Robert Lindsay
• Introduction
• Development of Long-acting Insulin Analogues
• Long-acting Insulin Analogues
• Meta-analysis of Glycaemic Efficacy of Long-acting Insulin Analogues
• Safety of Long-acting Insulin Analogues
• The Place of Long-acting Insulin Analogues in Current and Future Practice

10. Devices

• David Carty
• Introduction
• Insulin Pens
• Insulin Pumps
• Self-monitoring of Blood Glucose
• Linkage of Continuous Glucose Monitoring to Insulin Pumps
• Guidelines on the Use of Devices
• Place of Devices in Current and Future Practice

11. Acarbose and alpha glucosidase inhibitors

• Miles Fisher
• Introduction
• Pharmacology
• Glycaemic Efficacy
• Place of Alpha Glucosidase Inhibitors in Current and Future Practice

12. Glitazones and glitazars

• Miles Fisher
• Introduction
• Pharmacology
• Glycaemic Efficacy
• Safety and Side Effects
• Glitazars
• Place of Glitazones and Glitazars in Current and Future Practice

13. Other antidiabetic drugs

• Maroria Oroko, Andrea Llano, and Miles Fisher
• Introduction
• Pramlintide
• Colesevelam
• Bromocriptine
• Hydroxychloroquine
• Antiobesity Drugs
• Place of Other Drugs in Current and Future Practice

14. Future antidiabetic drugs

• Emma Johns and Miles Fisher
• Introduction
• Dual and Triple Agonists
• Imeglimin
• Place of New Antidiabetic Drugs in Future Practice

15. Guidelines on antidiabetic drugs

• Miles Fisher and Russell Drummond
• Introduction
• Guidelines on the Use of Antidiabetic Drugs in Type 2 Diabetes
• Guidelines on the Management of Type 1 Diabetes
• Special Patient Groups
• Place of Guidelines in Current and Future Practice

16. Prescribing antidiabetic drugs

• Andrea Llano, Gerry McKay, Frances McManus, Catriona McClements, Joyce McKenzie, and Deborah Morrison
• Introduction
• Therapeutic Inertia
• Polypharmacy
• Nonadherence
• The Patient with Problematic Hypoglycaemia
• Prescribing in Renal Impairment
• Prescribing in Liver Disease
• Prescribing in Cardiovascular Disease
• Prescribing in Pregnancy
• Prescribing in the Young
• Prescribing in the Elderly
• The Patient with Type 1 Diabetes: a Therapeutic Journey (an Illustrative Case)
• The Patient with Type 2 Diabetes: a Therapeutic Journey (an Illustrative Case)
• Future Developments in Prescribing in Diabetes

 

People also search for Diabetes Drug Notes 1st Edition:

sugar free cough syrup for diabetics in india
famous diabetes medicine
why do diabetics get free prescriptions
diabetes drug names
diabetes drugs mechanism of action pdf